CORRECTION article

Front. Mol. Biosci., 03 November 2022

Sec. Molecular Diagnostics and Therapeutics

Volume 9 - 2022 | https://doi.org/10.3389/fmolb.2022.1026319

Corrigendum: Transcription factors BARX1 and DLX4 contribute to progression of clear cell renal cell carcinoma via promoting proliferation and epithelial–mesenchymal transition

  • 1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • 2. Hubei Institute of Urology, Wuhan, China

  • 3. Department of Urology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

  • 4. Department of Urology, First Affiliated Hospital of Harbin Medical University, Harbin, China

  • 5. Department of Geriatric, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Article metrics

View details

964

Views

510

Downloads

In the published article, there was an error in Figure 6 as published. The images for “BARX1” in Figure 6C and “sh-BARX1-1” in Figure 6E were misplaced during the upload process. The corrected Figure 6 appears below.

FIGURE 6

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

transcription factor, BARX1, DLX4, biomarker, clear cell renal cell carcinoma

Citation

Sun G, Ge Y, Zhang Y, Yan L, Wu X, Ouyang W, Wang Z, Ding B, Zhang Y, Long G, Liu M, Shi R, Zhou H, Chen Z and Ye Z (2022) Corrigendum: Transcription factors BARX1 and DLX4 contribute to progression of clear cell renal cell carcinoma via promoting proliferation and epithelial–mesenchymal transition. Front. Mol. Biosci. 9:1026319. doi: 10.3389/fmolb.2022.1026319

Received

23 August 2022

Accepted

18 October 2022

Published

03 November 2022

Volume

9 - 2022

Edited and reviewed by

Sergio Akira Uyemura, University of São Paulo, Brazil

Updates

Copyright

*Correspondence: Hui Zhou,

†These authors have contributed equally to this work

This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics